Health Condition 1: J453- Mild persistent asthma
Conditions
Interventions
Intervention1: 1.Agashtya Haritaki Rasayana (AFI -I, API-II
Vol. IV): Dose:10 gms twice daily
Dosage form:Avaleha
Route of Administration:Oral
Time of Administration : Twice a day in empty Stomach
Anupana:Lukewarm Water
Packing form:Pet Jar
Duration of the
Vol. I): Dose:250 mg twice daily
Dosage form :Powder
Route of Administration:Oral
Time of Administration: Twice a day along with 10gm of Agashtya Haritaki rasayana
Packing form :Pet Bottle
Duration
Sponsors
Central Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients of either sex with age between 18 to 60 years. 2.Diagnosed cases of the mild predominant or persistent stable Bronchial Asthma (Tamaka Shwasa) (as per GINA Guideline) (Stable asthma controller therapy dose i.e no changes in regular anti-asthma medication & Symptoms: 3.FEV1 >80% of the predicted value 4.Patients willing to participate and written consent.
Exclusion criteria
Exclusion criteria: 1.Patients with FEV1 2.Patients with uncontrolled Diabetes Mellitus having HbA1C > 8% 3.Patients who have history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 4.Symptomatic patients with clinical evidence of Heart failure 5.Known cases of HIV and AIDS. 6.Known cases of malignancy 7.Patient taking participation in any other clinical trial. 8.Women who are planning for conception / pregnant or lactating. 9.Patients with concurrent serious hepatic disorders (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease (COPD) 10.H/o hypersensitivity to any of the trial drugs or their ingredients 11.Any other condition which the Investigator thinks may jeopardize the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in Asthma Control Questionnaire (ACQ) 2. Frequency of need for control medication Timepoint: On baseline,14th day,28th day, 42th day, 56th day, 70th day, 84th day and 98th day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Any improvement in FEV1 2.Changes in serum CRP, IgE 3.Frequency of need for rescue medication Timepoint: On baseline,14th day,28th day, 42th day, 56th day, 70th day, 84th day and 98th day | — |
Countries
India
Contacts
Public ContactDR HARBANS SINGH
CENTRAL AYURVEDA RESEARCH INSTITUTE FOR RESPIRATORY DISORDERS
Outcome results
None listed